|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Biotest AG-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
100% |
|
Biotest AG-Deals & Alliances Report
|
Mar 2011 |
£380 |
99% |
Biotest AG - Product Pipeline Review
Q4 2010
|
Nov 2010 |
£315 |
99% |
Multiple Myeloma (Kahler's Disease) - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
75% |
Neutropenia Global Clinical Trials Review
Q4, 2010
|
Dec 2010 |
£630 |
74% |
Liver Transplantation Global Clinical Trials Review
H1, 2012
|
Jan 2012 |
£630 |
73% |
Hodgkin Lymphoma Global Clinical Trials Review
H2, 2011
|
Nov 2011 |
£630 |
73% |
Chronic Plaque Psoriasis Global Clinical Trials Review
H2, 2011
|
Oct 2011 |
£630 |
73% |
Primary Immune Deficiency (PID) - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
73% |
Psoriasis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
72% |
|
Monoclonal Antibody Based Products
|
Oct 2008 |
£2,500 |
68% |
Monoclonal Antibody Based Products
Global Trends
|
Nov 2009 |
£1,895 |
68% |
Chronic Plaque Psoriasis - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
68% |
Systemic Lupus Erythematosus - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
65% |
Coagulation Disorders Market to 2017
Hemophilia A, The Largest Segment, to Witness a Decline in Growth Rate Due to Patent Expiries and Weak Pipeline
|
Sep 2011 |
£2,215 |
64% |
Immunoglobulins Market to 2017
off-Label Usage and Treatment of Primary Immunodeficiency Diseases and Neurological Disorders Stimulate Market Growth
|
Sep 2011 |
£2,215 |
60% |
|
Intravenous (IV) Solutions
|
Aug 2011 |
£3,035 |
59% |
Multiple Myeloma - Pipeline Review
Q3 2011
|
Jul 2011 |
£315 |
58% |
Critical Care Market to 2017
Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles
|
Sep 2011 |
£2,215 |
57% |
Rheumatoid Arthritis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
56% |
|
Bio-Rad Laboratories, Inc. Market Share Analysis
|
Dec 2011 |
£630 |
54% |
Sarcomas - Pipeline Review
Q3 2011
|
Jul 2011 |
£315 |
54% |
|
Immunochemicals
|
Apr 2011 |
£2,845 |
54% |
Next-Generation Antibody Therapies: Pipeline and Market
2011-2021
|
Nov 2011 |
£1,699 |
51% |
|
Molecular Diagnostics: Major World Markets
|
Feb 2007 |
£2,525 |
51% |
|
Blood Banking & Blood Products
|
Oct 2008 |
£2,500 |
50% |
|
The Blood Industry
|
Mar 2011 |
£3,065 |
50% |
Antibody-Drug Conjugates 2011 - real breakthrough still to come
A Technology, Stakeholder and R&D Pipeline Analysis
|
Sep 2011 |
£1,620 |
49% |
Worldwide Market for In Vitro Diagnostic Tests
7th Edition
|
Jul 2010 |
£3,160 |
48% |
Biopharmaceuticals
A Global Market Overview
|
Apr 2010 |
£2,960 |
46% |
